JonesTrading analyst Soumit Roy maintained a Buy rating on HCW Biologics (HCWB – Research Report) today and set a price target of $8.00. The company’s shares closed today at $2.16.
According to TipRanks, Roy is a 4-star analyst with an average return of 9.8% and a 35.07% success rate. Roy covers the Healthcare sector, focusing on stocks such as Curis, Aeglea Biotherapeutics, and Day One Biopharmaceuticals.
HCW Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00, which is a 178.42% upside from current levels. In a report released on November 8, Maxim Group also maintained a Buy rating on the stock with a $4.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $3.32 and a one-year low of $1.76. Currently, HCW Biologics has an average volume of 24.51K.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HCWB in relation to earlier this year. Earlier this month, Byam Rebecca, the CFO of HCWB bought 33,750.00 shares for a total of $4,725.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HCW Biologics Inc is a preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases. It is developing HCW9218 as an injectable immunotherapeutic for patients with solid tumors.
Read More on HCWB:
- HCW Biologics to poster presentation from Phase 1 trial of HCW9218
- Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting
- HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights
- HCW Biologics initiated with a Buy at JonesTrading
